公司资料
Sagimet Biosciences 股价、新闻与催化剂
- 股票代码:
- SGMT
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
10.43 USD (-1.14%)
收盘价
最后更新: 2026年8月17日
419M USD
市值
股价为何变动
The latest monitored company update is “Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).” The corresponding closing-price reaction is not yet available.
公司概览
Metabolic Pathway Therapeutics
Sagimet Biosciences develops fatty acid synthase inhibitors for diseases driven by abnormal lipid production.
Denifanstat
Denifanstat is an oral FASN inhibitor that reduces de novo lipogenesis and has been studied in both metabolic liver disease and dermatology.
Dermatology Focus
Sagimet is prioritizing moderate-to-severe acne, where reduced sebaceous lipid synthesis may address an upstream disease mechanism.
未来催化剂
- A U.S. Phase 3 study of denifanstat in moderate-to-severe acne is planned to begin in the second half of 2026.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。